I think no one has ever looked but there are other GPR109A agonists with little or no meaningful lipid-altering effects, so not sure this is due to lower affinity or maybe it's not the only MOA of niacin's effect on lipids. probably both. I would think that investigating this point is important for patients with severe psoriasis as they are at increased risk of cardiovascular mortality. Are you going to take this suggestion to ABT/BIIB or shall I? :-)
Market Data 
Markets 
AI
